Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 3/20 | 0.42 |
| ▸ | CES1 | P23141 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11194848 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL6744028 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL15657593 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL23521355 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL15660116 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL23521354 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL15659443 | 0.93 | MAPT (0.49) | LMNAMAPTFFAR4FFAR1CES2 | |
| SCHEMBL5193244 | 0.91 | EPHX2 (0.52) | LMNAMAPTFFAR4FFAR1MEN1 | |
| SCHEMBL5193248 | 0.91 | EPHX2 (0.52) | LMNAMAPTFFAR4FFAR1MEN1 | |
| SCHEMBL11787069 | 0.91 | MAPT (0.46) | LMNAMAPTFFAR4FFAR1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1149892-B1 | SURFACTANT COMPOSITION | KAO CORP (JP) | 2007-04-04 | — | — | EP | disclosed |
| US-6946430-B2 | Surfactant composition | KAO CORPORATION (JP) | 2005-09-20 | — | — | US | disclosed |
| US-20020187915-A1 | Surfactant composition | KAO CORPORATION (JP) | 2002-12-12 | — | — | US | disclosed |
| US-6407054-B2 | Surfactant composition | KAO CORPORATION (JP) | 2002-06-18 | — | — | US | disclosed |
| EP-1149892-A1 | SURFACTANT COMPOSITION | Kao Corporation (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-20010034310-A1 | Surfactant composition | KAO CORPORATION (JP) | 2001-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034310-A1 | Surfactant composition | DEGS1, SGMS1, LIPA | LMNA 1397/4885MAPT 4311/4885FFAR4 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.